68 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
3 Jan 06
Represents strategic decision to control manufacturing of Surfaxinâ and SRT pipeline
12:00am
life cycle management of Surfaxin for new indications, potential formulation enhancements, and expansion of our aerosol SRT products beginning
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
15 Feb 08
Discovery Labs Reports Fourth Quarter 2007 Financial Results
12:00am
.
The Company’s top priority is to gain FDA approval of Surfaxin. We also intend to expand Surfaxin use through life-cycle management and continue
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
3 Aug 11
Results of Operations and Financial Condition
12:00am
.
SURFAXIN LSTM (lyophilized lucinactant) for neonatal RDS: SURFAXIN LS is an important life-cycle development program intended to further improve upon
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
9 Nov 10
Results of Operations and Financial Condition
12:00am
Programs: Surfaxin LS (lyophilized lucinactant) is an important life-cycle initiative, intended to further improve on the Surfaxin product profile